James H. Doroshow

15Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

6.4Author DataRank

Indexed papers

22in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 22 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

Cancer Research(2017)10.1158/0008-5472.can-17-0582

Top 6%

4.0DataRank

Top 6%130 citations

Nathalie Conte, Giorgio Inghirami, Mark A. Murakami, Sebastian Brabetz, Zhiping Gu +57 more

Papers

Driven by 112 papers — median percentile 0. Top paper: “Hepatic metastasis in granulosa cell tumor of the ovary”.

Hepatic metastasis in granulosa cell tumor of the ovary

Cancer(1985)10.1002/1097-0142(19850801)56:3<691::aid-cncr2820560342>3.0.co;2-q

N/A

4.9DataRank · unranked

39 citations

Hyun Y. Pak, Mark L. Esensten, James H. Doroshow, Kim A. Margolin

Genome-wide depletion of replication initiation events in highly transcribed regions

Genome Research(2011)10.1101/gr.124644.111

N/A

4.2DataRank · unranked

139 citations

Michael Ryan, RyangGuk Kim, Anna L. Zakas, Haiqing Fu, Chii Mei Lin +11 more

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

Cancer Research(2017)10.1158/0008-5472.can-17-0582

Top 6%

4.0DataRank

Top 6%130 citations

Nathalie Conte, Giorgio Inghirami, Mark A. Murakami, Sebastian Brabetz, Zhiping Gu +57 more

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

New England Journal of Medicine(2023)10.1056/nejmoa2303383

N/A

3.3DataRank · unranked

158 citations

Elad Sharon, Geraldine O’Sullivan Coyne, Nancy Moore, Jared C. Foster, James Hu +26 more

Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.11519

N/A

1.8DataRank · unranked

50 citations

Geraldine O’Sullivan Coyne, Nancy Moore, Elad Sharon, Naoko Takebe, Kristin Fino +15 more

Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial

Nature Medicine(2025)10.1038/s41591-024-03361-4

N/A

0.954DataRank · unranked

41 citations

Geraldine O’Sullivan Coyne, Eva Dombi, Cecilia Tibery, William G. Herrick, Staci Martin +30 more

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

Clinical Cancer Research(2010)10.1158/1078-0432.ccr-10-0523

N/A

0.834DataRank · unranked

258 citations

Asako J. Nakamura, Yong-Wei Zhang, Jiuping (Jay) Ji, William M. Bonner, Robert J. Kinders +4 more

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Nature Genetics(2021)10.1038/s41588-020-00750-6

N/A

0.790DataRank · unranked

193 citations

Jessica Giordano, Anuj Srivastava, Min Jin Ha, Michael W. Lloyd, Roebi de Bruijn +57 more

Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment

Cancer Cell(2020)10.1016/j.ccell.2020.10.015

N/A

0.698DataRank · unranked

104 citations

Naoko Takebe, Toshinori Hinoue, Katherine A. Hoadley, Maria Cardenas, Alina M. Hamilton +41 more

Ensemble transfer learning for the prediction of anti-cancer drug response

Scientific Reports(2020)10.1038/s41598-020-74921-0

N/A

0.689DataRank · unranked

98 citations

Thomas Brettin, Yvonne A. Evrard, Alexander Partin, Fangfang Xia, Maulik Shukla +4 more

Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0267

Top 29%

0.685DataRank

Top 29%24 citations

Mark W. Kunkel, Stephen L. White, Donn G. Wishka, Omar D. Lopez, Lori Bowles +16 more

DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors

Scientific Reports(2023)10.1038/s41598-023-32509-4

N/A

0.646DataRank · unranked

73 citations

Melinda G. Hollingshead, Dat Nguyen, Robert J. Kinders, James H. Doroshow, Sherry X. Yang +1 more

The beginning of GPX2 and 30 years later

Free Radical Biology and Medicine(2022)10.1016/j.freeradbiomed.2022.06.232

N/A

0.624DataRank · unranked

63 citations

James H. Doroshow, Fong‐Fong Chu, R. Steven Esworthy

Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0850

N/A

0.524DataRank · unranked

32 citations

James H. Doroshow, Susan Galbraith, Antoni Ribas, Paul G. Kluetz, Richard Pazdur +2 more

NADPH oxidase 1 is highly expressed in human large and small bowel cancers

PLoS ONE(2020)10.1371/journal.pone.0233208

N/A

0.505DataRank · unranked

28 citations

Guojian Jiang, Yongzhong Wu, Smitha Antony, Jennifer L. Meitzler, Ágnes Juhász +8 more

Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-20-0566

N/A

0.475DataRank · unranked

11 citations

Casey L. Kilpatrick, Melinda G. Hollingshead, Dominic Esposito, Geraldine O’Sullivan Coyne, Andrea M. Gross +7 more

Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0471

N/A

0.464DataRank · unranked

21 citations

Michael W. Lloyd, Soner Koc, Yvonne A. Evrard, Lisa M. McShane, Michael T. Lewis +29 more

Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas

Oncotarget(2020)10.18632/oncotarget.27784

N/A

0.457DataRank · unranked

20 citations

Shivaani Kummar, Robert Meehan, T. Khanh, Jerry M. Collins, Larry Anderson +20 more

Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adults

JNCI Journal of the National Cancer Institute(2025)10.1093/jnci/djaf214

Top 42%

0.448DataRank

Top 42%7 citations

Subhashini Jagu, Malcolm A. Smith, John Shern, Douglas S. Hawkins, Elaine R. Mardis +26 more

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2145

N/A

0.416DataRank · unranked

15 citations

Naoko Takebe, Shivaani Kummar, Albiruni R. Abdul Razak, Sant P. Chawla, Suzanne George +13 more

Initial reporting from the prospective National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.6565

Top 45%

0.406DataRank

Top 45%5 citations

Ana F. Best, Sacha Gnjatic, Andrea Denicoff, Grace Mishkin, Melissa Bowman +15 more

ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomide

Oncotarget(2021)10.18632/oncotarget.28090

N/A

0.385DataRank · unranked

12 citations

Curtis Hose, John Connelly, Erik Harris, Anne Monks, Angie B. Dull +10 more

Role of the microbiota in ileitis of a mouse model of inflammatory bowel disease—Glutathione peroxide isoenzymes 1 and 2‐double knockout mice on a C57BL background

MicrobiologyOpen(2020)10.1002/mbo3.1107

N/A

0.378DataRank · unranked

8 citations

R. Steven Esworthy, Binghui Shen, James H. Doroshow, Fong‐Fong Chu

Phase 1 study of Z-Endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors

Oncotarget(2021)10.18632/oncotarget.27887

N/A

0.360DataRank · unranked

10 citations

Geraldine O’Sullivan Coyne, Shivaani Kummar, Jerry M. Collins, Joel M. Reid, Richard Piekarz +18 more

Phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3088

N/A

0.358DataRank · unranked

5 citations

Geraldine O’Sullivan Coyne, Naoko Takebe, Abdul Rafeh Naqash, Jessica Mukherjee, Ashley Bruns +12 more

Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors

Science Signaling(2025)10.1126/scisignal.ado2857

N/A

0.345DataRank · unranked

9 citations

Meghri Katerji, Marwa M. Afifi, Katherine M. Nyswaner, Carolyn C. Woodroofe, Zoe C. Edwards +22 more

Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors

Cancer Chemotherapy and Pharmacology(2023)10.1007/s00280-023-04600-0

N/A

0.314DataRank · unranked

6 citations

Geraldine O’Sullivan Coyne, Jennifer Zlott, Shivaani Kummar, Robert Meehan, Larry Rubinstein +13 more

Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors

Investigational New Drugs(2021)10.1007/s10637-021-01138-x

N/A

0.312DataRank · unranked

7 citations

Apurva K. Srivastava, Tony Navas, Fabiola Cecchi, Young Ho Lee, Donald P. Bottaro +11 more

Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04778-5

N/A

0.258DataRank · unranked

4 citations

Shivaani Kummar, Larry Rubinstein, Deborah Wilsker, Nancy Young Moore, Murielle Hogu +16 more

TPWshiny: an interactive R/Shiny app to explore cell line transcriptional responses to anti-cancer drugs

Bioinformatics(2021)10.1093/bioinformatics/btab619

Top 62%

0.225DataRank

Top 62%3 citations

Alida Palmisano, Ravindra Kumar, Ming‐Chung Li, James H. Doroshow, Yingdong Zhao +1 more

A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis

Cancer Research(2024)10.1158/0008-5472.can-23-1349

Top 62%

0.222DataRank

Top 62%3 citations

Xing Yi Woo, Soner Koc, Todd Sheridan, Steven B. Neuhauser, Shidan Wang +49 more

A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11528

N/A

0.208DataRank · unranked

3 citations

Anthony P. Conley, James Lin Chen, Elizabeth J. Davis, Melissa Burgess, Albiruni Ryan Abdul Razak +13 more

Role of Reactive Oxygen Species in the Cytotoxicity of Arsenic Trioxide and Pamidronate for Human Prostate Cancer Cells

PubMed(2020)10.20455/ros.2020.811

N/A

0.208DataRank · unranked

3 citations

Shikha Gaur, James H. Doroshow

ROADMAPS: An Online Database of Response Data, Dosing Regimens, and Toxicities of Approved Oncology Drugs as Single Agents to Guide Preclinical In Vivo Studies

Cancer Research(2022)10.1158/0008-5472.can-21-4151

Top 65%

0.194DataRank

Top 65%2 citations

Nathaniel Greenberg, Michelle Gottholm-Ahalt, Richard Camalier, Barry C. Johnson, Jerry M. Collins +2 more

PDXNet Portal: Patient-Derived Xenograft model, data, workflow, and tool discovery

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.10.15.464537

Top 72%

0.110DataRank

Top 72%1 citations

Michael W. Lloyd, Jeffrey Grover, Sara Seepo, Sai Lakshmi Subramanian, Manisha Ray +34 more

Evaluating the indotecan–neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal Emax regressions

Cancer Chemotherapy and Pharmacology(2023)10.1007/s00280-023-04509-8

N/A

0.104DataRank · unranked

1 citations

Benjamin C. Kennard, Julianne L. Holleran, Nancy Young Moore, Jennifer Zlott, Brian Miller +7 more

Blood-based assessment of patients with mismatch repair-deficient tumors enrolled in NCI-MATCH Arm Z1D (nivolumab).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2560

Top 78%

0.104DataRank

Top 78%1 citations

Jennifer L. Silhavy, Jennifer S. LoCoco, Biswajit Das, Sorena Rahmanian, Ting-Chia Chang +15 more

A phase 2 study of an anti–PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11533

N/A

0.104DataRank · unranked

1 citations

Brian Ko, Brian A. Van Tine, Anthony P. Conley, Elizabeth J. Davis, Melissa Burgess +12 more

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0329

N/A

0DataRank · unranked

71 citations

Abdul Rafeh Naqash, Geraldine O’Sullivan Coyne, Shivaani Kummar, T. Khanh, Ashley Bruns +19 more

A cross-study analysis of drug response prediction in cancer cell lines

Briefings in Bioinformatics(2021)10.1093/bib/bbab356

N/A

0DataRank · unranked

99 citations

Jonathan Allen, Prasanna Balaprakash, Thomas Brettin, Cristina García–Cardona, Austin Clyde +19 more

Learning curves for drug response prediction in cancer cell lines

BMC Bioinformatics(2021)10.1186/s12859-021-04163-y

N/A

0DataRank · unranked

4 citations

Thomas Brettin, Yvonne A. Evrard, Yitan Zhu, Hyunseung Yoo, Fangfang Xia +7 more

The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment

Cell(2021)10.1016/j.cell.2021.02.055

N/A

0DataRank · unranked

188 citations

Jean C. Zenklusen, Louis M. Staudt, James H. Doroshow, Douglas R. Lowy, Henry Rodriguez

Converting tabular data into images for deep learning with convolutional neural networks

Scientific Reports(2021)10.1038/s41598-021-90923-y

N/A

0DataRank · unranked

198 citations

Thomas Brettin, Fangfang Xia, Alexander Partin, Maulik Shukla, Hyunseung Yoo +4 more

TPM, FPKM, or Normalized Counts? A Comparative Study of Quantification Measures for the Analysis of RNA-seq Data from the NCI Patient-Derived Models Repository

Journal of Translational Medicine(2021)10.1186/s12967-021-02936-w

N/A

0DataRank · unranked

524 citations

Ming‐Chung Li, Mariam M. Konaté, Li Chen, Biswajit Das, Chris Karlovich +5 more

Genomic characterization of preclinical models derived from primary and metastatic sites from rapid autopsy patients in PDMR.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e13506

Top 100%

0DataRank

Top 100%0 citations

Rajesh Patidar, Biswajit Das, Yvonne A. Evrard, Chris Karlovich, Tomas Vilimas +15 more

Initial report on hospitalized cancer patients with COVID-19 from the National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.6566

Top 100%

0DataRank

Top 100%0 citations

Ana F. Best, Alok A. Khorana, Steven A. Pergam, Grace Mishkin, Melissa Bowman +8 more

Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials

The Lancet(2022)10.1016/s0140-6736(22)01390-3

N/A

0DataRank · unranked

68 citations

Ruitao Lin, Christopher R. Flowers, Shanda Finnigan, Lisa M. Cordes, Yoko Fukuda +7 more

Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3624

N/A

0DataRank · unranked

4 citations

Arjun Mittra, Geraldine O’Sullivan Coyne, Li Chen, Biswajit Das, Shivaani Kummar +15 more

Comparative Oncology Assessment of a Novel Inhibitor of Valosin-Containing Protein in Tumor-Bearing Dogs

Molecular Cancer Therapeutics(2022)10.1158/1535-7163.mct-22-0167

N/A

0DataRank · unranked

10 citations

Christina Mazcko, Timothy M. Fan, David M. Vail, Brian K. Flesner, Jeffrey N. Bryan +14 more

Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3612

N/A

0DataRank · unranked

24 citations

Andrea M. Gross, Eva Dombi, Cecilia Tibery, Amanda Carbonell, Naoko Takebe +13 more

Circulating tumor DNA sequencing provides comprehensive mutation profiling for pediatric central nervous system tumors

npj Precision Oncology(2022)10.1038/s41698-022-00306-3

N/A

0DataRank · unranked

11 citations

Robin A. Harrington, Augustine Eze, Miriam Bornhorst, Cassie Kline, Heather Gordish‐Dressman +14 more

Patterns of Enrollment in Cancer Treatment Trials During the COVID-19 Pandemic at National Cancer Institute–Designated Cancer Centers

The Cancer Journal(2022)10.1097/ppo.0000000000000578

N/A

0DataRank · unranked

10 citations

Gisele A. Sarosy, David Loose, Henry Ciolino, James H. Doroshow, Sheila A. Prindiville

3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) Positron Emission Tomography as an In Vivo Biomarker of inhibition of CDK 4/6-Rb pathway by Palbociclib in a patient derived bladder tumor

Journal of Translational Medicine(2022)10.1186/s12967-022-03580-8

N/A

0DataRank · unranked

5 citations

Joseph D. Kalen, Paula Jacobs, Lisa Riffle, Amy James, Lai Thang +6 more

Extended progression-free survival and long-term safety of nirogacestat in patients with desmoid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11545

N/A

0DataRank · unranked

5 citations

Shivaani Kummar, Seth M. Steinberg, Murielle Hogu, Naoko Takebe, Amisha Shah +3 more

Data from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

(2023)10.1158/0008-5472.c.6510291.v1

Top 100%

0DataRank

Top 100%0 citations

Nathalie Conte, Giorgio Inghirami, Mark A. Murakami, Sebastian Brabetz, Zhiping Gu +59 more

Safety, pharmacodynamic, and clinical response evaluation of nilotinib and paclitaxel in adults with refractory solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3026

N/A

0DataRank · unranked

1 citations

Geraldine O’Sullivan Coyne, Shivaani Kummar, Murielle Hogu, Larry Rubinstein, Sarah Miller +15 more

Blood-based detection of actionable alterations from NCI-MATCH patients with no tissue results.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3035

N/A

0DataRank · unranked

0 citations

Amanda Peach, D. A. HOWELL, Biswajit Das, Rini Pauly, Ting-Chia Chang +14 more

Drug response prediction in patient-derived xenografts with data augmentation and multimodal deep learning.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e13572

N/A

0DataRank · unranked

0 citations

Thomas Brettin, Yitan Zhu, Maulik Shukla, Fangfang Xia, Hyunseung Yoo +7 more

Bringing experimental therapeutics clinical trials network (ETCTN) to underrepresented population.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.6542

Top 100%

0DataRank

Top 100%0 citations

Gary C. Doolittle, Rahul Atul Parikh, Anup Kasi, Elizabeth Wulff‐Burchfield, Benjamin Powers +15 more

A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.10.26.512745

Top 100%

0DataRank

Top 100%0 citations

X. Woo, Soner Koc, Todd Sheridan, Steven B. Neuhauser, Shidan Wang +45 more

Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology(2020)10.1007/s00280-020-04073-5

N/A

0DataRank · unranked

26 citations

Lihua Wang, Jennifer Zlott, Lamin Juwara, Joseph M. Covey, Jan H. Beumer +18 more

Enhanced Co-Expression Extrapolation (COXEN) Gene Selection Method for Building Anti-Cancer Drug Response Prediction Models

Genes(2020)10.3390/genes11091070

N/A

0DataRank · unranked

14 citations

Thomas Brettin, Yvonne A. Evrard, Fangfang Xia, Alexander Partin, Maulik Shukla +4 more

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3334

N/A

0DataRank · unranked

59 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Redox phospholipidomics discovers pro-ferroptotic death signals in A375 melanoma cells in vitro and in vivo

Redox Biology(2023)10.1016/j.redox.2023.102650

N/A

0DataRank · unranked

50 citations

Alexandr A. Kapralov, Vladimir A. Tyurin, Galina V. Shurin, Andrew A. Amoscato, Dhivyaa Rajasundaram +10 more

Effect of Anticancer Quinones on Reactive Oxygen Production by Adult Rat Heart Myocytes

Oxidative Medicine and Cellular Longevity(2020)10.1155/2020/8877100

N/A

0DataRank · unranked

12 citations

James H. Doroshow

Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs

Cancer Research Communications(2023)10.1158/2767-9764.crc-23-0193

N/A

0DataRank · unranked

18 citations

Nathan P. Coussens, Thomas Silvers, John Wright, Joel Morris, James H. Doroshow +2 more

Exogenous DNA enhances DUOX2 expression and function in human pancreatic cancer cells by activating the cGAS-STING signaling pathway

Free Radical Biology and Medicine(2023)10.1016/j.freeradbiomed.2023.06.012

N/A

0DataRank · unranked

16 citations

Yongzhong Wu, Mariam M. Konaté, Jiamo Lu, David J. Mallick, Smitha Antony +8 more

Data augmentation and multimodal learning for predicting drug response in patient-derived xenografts from gene expressions and histology images

Frontiers in Medicine(2023)10.3389/fmed.2023.1058919

N/A

0DataRank · unranked

13 citations

Thomas Brettin, Yitan Zhu, James M. Dolezal, Sara Kochanny, Alexander T. Pearson +5 more

Integration of Computational Docking into Anti-Cancer Drug Response Prediction Models

Cancers(2023)10.3390/cancers16010050

N/A

0DataRank · unranked

9 citations

Yitan Zhu, Thomas Brettin, Yvonne A. Evrard, Alexander Partin, Maulik Shukla +6 more

COVID-19, Social Justice, and Clinical Cancer Research

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa162

N/A

0DataRank · unranked

19 citations

Sheila A. Prindiville, Worta McCaskill‐Stevens, Margaret Mooney, Patrick J. Loehrer, James H. Doroshow

Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3022

N/A

0DataRank · unranked

2 citations

Alice P. Chen, Shivaani Kummar, Murielle Hogu, Larry Rubinstein, Naoko Takebe +15 more

Phase 2 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with granulosa cell ovarian cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5564

N/A

0DataRank · unranked

1 citations

Geraldine O’Sullivan Coyne, Jennifer Zlott, Mohamad A. Salkeni, Naoko Takebe, Ning Ma +12 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v1

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts

(2023)10.1158/1078-0432.c.6517116.v1

Top 100%

0DataRank

Top 100%0 citations

Melinda G. Hollingshead, Sonny Khin, Larry Rubinstein, Joseph E. Tomaszewski, James H. Doroshow +2 more

Data from Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells

(2023)10.1158/1078-0432.c.6519651

N/A

0DataRank · unranked

0 citations

Thomas D. Pfister, Ralph E. Parchment, Shivaani Kummar, Larry Rubinstein, Yvonne A. Evrard +6 more

Data from Phase 0 Trials: Expediting the Development of Chemoprevention Agents

(2023)10.1158/1940-6207.c.6544881

Top 100%

0DataRank

Top 100%0 citations

James H. Doroshow, Shivaani Kummar

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v2

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

5-Aza-4’-thio-2’-deoxycytidine induces C>G transversions in a specific trinucleotide context and leads to acute lymphoid leukemia

Research Square(2023)10.21203/rs.3.rs-3186246/v1

N/A

0DataRank · unranked

0 citations

Ryan Bertoli, Yang Jo Chung, Michael J. Difilippantonio, Anthony Wokasch, Madison R.B. Marasco +8 more

HTS384 NCI60: The Next Phase of the NCI60 Screen

Cancer Research(2024)10.1158/0008-5472.can-23-3031

N/A

0DataRank · unranked

24 citations

Nathan P. Coussens, Joel Morris, Ronald C. Taylor, Thomas S. Dexheimer, Eric M. Jones +3 more

Supplementary Video S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

Figshare(2024)10.1158/0008-5472.26326771.v1

N/A

0DataRank · unranked

0 citations

Nathalie Conte, Giorgio Inghirami, Mark A. Murakami, Sebastian Brabetz, Zhiping Gu +58 more

The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development

Cancer Research(2024)10.1158/0008-5472.can-23-2785

N/A

0DataRank · unranked

7 citations

Yang Jo Chung, Michael J. Difilippantonio, Anthony Wokasch, Madison R.B. Marasco, Haley Klimaszewski +10 more

Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor

SLAS DISCOVERY(2024)10.1016/j.slasd.2024.100186

N/A

0DataRank · unranked

7 citations

Nathan P. Coussens, Thomas Silvers, Eric M. Jones, Li Chen, Jianwen Fang +5 more

NCI workshop on ctDNA in cancer treatment and clinical care

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae179

N/A

0DataRank · unranked

5 citations

Jung S. Byun, V. Anne Westbrook, James V. Tricoli, James H. Doroshow, Lyndsay N. Harris +1 more

Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors

Epigenetics(2024)10.1080/15592294.2024.2309824

N/A

0DataRank · unranked

6 citations

Yingdong Zhao, Kyle Roney, Weimin Zhu, Alan Brooks, Deborah Wilsker +4 more

S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

Figshare(2024)10.1158/0008-5472.26326774.v1

N/A

0DataRank · unranked

0 citations

Nathalie Conte, Giorgio Inghirami, Mark A. Murakami, Sebastian Brabetz, Zhiping Gu +57 more

Streamlining the conduct of cancer clinical trials: new standard data collection practices for National Cancer Institute late-phase clinical studies

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae239

N/A

0DataRank · unranked

3 citations

Sumithra J. Mandrekar, Neal J. Meropol, Andrea Denicoff, Oren Grad, Judith A Hautala +2 more

The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers

Cancer Chemotherapy and Pharmacology(2024)10.1007/s00280-024-04651-x

N/A

0DataRank · unranked

1 citations

Naoko Takebe, Alice P. Chen, Shivaani Kummar, Richard Piekarz, Brian F. Kiesel +5 more

Data Imbalance in Drug Response Prediction - Multi-Objective Optimization Approach in Deep Learning Setting

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.03.14.585074

N/A

0DataRank · unranked

1 citations

Yitan Zhu, Thomas Brettin, Yvonne A. Evrard, Alexander Partin, Fangfang Xia +5 more

Supplementary Video S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

(2024)10.1158/0008-5472.26366789

N/A

0DataRank · unranked

0 citations

Nathalie Conte, Giorgio Inghirami, Mark A. Murakami, Sebastian Brabetz, Zhiping Gu +57 more

Data from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

(2024)10.1158/0008-5472.c.6510291

Top 100%

0DataRank

Top 100%0 citations

Nathalie Conte, Giorgio Inghirami, Mark A. Murakami, Sebastian Brabetz, Zhiping Gu +58 more

Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids

SLAS DISCOVERY(2025)10.1016/j.slasd.2025.100222

N/A

0DataRank · unranked

9 citations

Zahra Davoudi, Nathan P. Coussens, Thomas Silvers, Joel Morris, Naoko Takebe +5 more

S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

Figshare(2023)10.1158/0008-5472.22419099.v1

N/A

0DataRank · unranked

0 citations

Nathalie Conte, Giorgio Inghirami, Mark A. Murakami, Sebastian Brabetz, Zhiping Gu +58 more

S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

(2023)10.1158/0008-5472.22419099

N/A

0DataRank · unranked

0 citations

Nathalie Conte, Giorgio Inghirami, Mark A. Murakami, Sebastian Brabetz, Zhiping Gu +57 more

Combinatorial screen with apoptosis pathway targeted agents alrizomadlin, pelcitoclax, and dasminapant in multi-cell type tumor spheroids

SLAS DISCOVERY(2025)10.1016/j.slasd.2025.100230

N/A

0DataRank · unranked

5 citations

Thomas S. Dexheimer, Thomas Silvers, Phillip R. Sanchez, Li Chen, Melinda G. Hollingshead +4 more

RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Cancer Research Communications(2025)10.1158/2767-9764.crc-24-0582

N/A

0DataRank · unranked

1 citations

Thomas S. Dexheimer, Nathan P. Coussens, Thomas Silvers, Raymond G. Fox, Samantha B. Kemp +7 more

High-throughput combination screening of Pidnarulex and other G-quadruplex ligands in multi-cell type tumor spheroids

SLAS DISCOVERY(2025)10.1016/j.slasd.2025.100284

N/A

0DataRank · unranked

1 citations

Nathan P. Coussens, Thomas Silvers, Poorva Juneja, Eric A. Jones, Steven D. Gore +4 more

Polymerase Ѳ inhibitors combinations with approved and investigational agents in patient-derived tumor multi-cell type (mct) spheroids

Experimental and Molecular Pathology(2025)10.1016/j.yexmp.2025.104978

N/A

0DataRank · unranked

2 citations

Thomas S. Dexheimer, Li Chen, Thomas Silvers, Eric M. Jones, Nathan P. Coussens +3 more

Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models

Frontiers in Oncology(2025)10.3389/fonc.2025.1571635

N/A

0DataRank · unranked

1 citations

Sergio Y. Alcoser, MICHAEL E. MULLENDORE, Li Chen, Chih-Jian Lih, Vishnuprabha Rahul Kannan +18 more

Phase 1 study of recombinant interleukin 15 in combination with nivolumab and ipilimumab in subjects with refractory cancers.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.2617

N/A

0DataRank · unranked

0 citations

Geraldine O’Sullivan Coyne, Ashley Bruns, Larry Rubinstein, Naoko Takebe, Sarah J. Shin +10 more

Phase 2 evaluation of the nilotinib-paclitaxel combination in patients with rare solid tumors: Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors trial 1 (RARE CANCER 1).

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.3015

N/A

0DataRank · unranked

0 citations

Andre DeSouza, Jared C. Foster, Naoko Takebe, Geraldine O’Sullivan Coyne, Sarah Miller +8 more

Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors (RARE CANCER) trial: RARE 2 talazoparib and temozolomide.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.3155

N/A

0DataRank · unranked

0 citations

Jennifer Zlott, Jared C. Foster, Sarah J. Shin, Geraldine O’Sullivan Coyne, Naoko Takebe +5 more

Targeted therapy combinations with ipatasertib in multi-cell type 3D tumor spheroid models

Academia oncology.(2025)10.20935/acadonco7726

N/A

0DataRank · unranked

0 citations

Naoko Takebe, Thomas S. Dexheimer, Thomas Silvers, Nathan P. Coussens, Melinda G. Hollingshead +2 more

Azanucleoside treatment leads to B-cell precursor acute lymphoblastic leukemia

Blood Neoplasia(2025)10.1016/j.bneo.2025.100161

N/A

0DataRank · unranked

0 citations

Ryan Bertoli, Olivia Tuckey, Yuelin J. Zhu, Robert L. Walker, Michael J. Difilippantonio +4 more

RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04800-w

N/A

0DataRank · unranked

0 citations

Thomas S. Dexheimer, Thomas Silvers, Nathan P. Coussens, Eric M. Jones, Steven D. Gore +3 more

S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

(2024)10.1158/0008-5472.26366795

N/A

0DataRank · unranked

0 citations

Nathalie Conte, Giorgio Inghirami, Mark A. Murakami, Sebastian Brabetz, Zhiping Gu +58 more

Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein

Nature Communications(2021)10.1038/s41467-021-26993-3

N/A

0DataRank · unranked

23 citations

Meghan F. Anderman, Disha Bhargava, Luciarita Boccuzzi, Xiaolan Qian, Dunrui Wang +8 more

S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

Figshare(2024)10.1158/0008-5472.26366795.v1

N/A

0DataRank · unranked

0 citations

Nathalie Conte, Giorgio Inghirami, Mark A. Murakami, Sebastian Brabetz, Zhiping Gu +57 more

TET2 and DNMT3A mutations and exceptional response to 4′-thio-2′-deoxycytidine in human solid tumor models

Journal of Hematology & Oncology(2021)10.1186/s13045-021-01091-5

N/A

0DataRank · unranked

12 citations

Melinda G. Hollingshead, Larry Rubinstein, Dat Nguyen, Angelo B. A. Larenjeira, Robert J. Kinders +3 more

Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial

JCO Precision Oncology(2021)10.1200/po.20.00372

N/A

0DataRank · unranked

45 citations

Shivaani Kummar, Nancy Moore, Larry Rubinstein, Yingdong Zhao, P. Mickey Williams +20 more

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2480

N/A

0DataRank · unranked

27 citations

Shivaani Kummar, James Hu, Kristen Ganjoo, Warren A. Chow, Khanh T. Do +17 more

Format (2D vs 3D) and media effect target expression and response of patient-derived and standard NSCLC lines to EGFR inhibitors

Cancer Treatment and Research Communications(2021)10.1016/j.ctarc.2021.100463

N/A

0DataRank · unranked

11 citations

James H. Doroshow, Beverly A. Teicher, Gurmeet Kaur

James H. Doroshow

Indexed papers

Top data-sharing exemplar

Papers